All In Biotech

BLA 020280 · Pharmacia

Genotropin Preservative Free

Somatropin · Injection

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Aug 24, 1995

Approved uses

6

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

53,357

11,105 serious, 900 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 4, 2026.

GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature ( 1.1 ) • Adult: Treatment of adults with either adult onset or childhood onset GHD ( 1.2 ) 1.1 Pediatric Patients GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing [see Contraindications (4) ] . GENOTROPIN is indicated for the treatment of growth failure in pediatric patients born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years. GENOTROPIN is indicated for the treatment of growth failure associated with Turner syndrome. GENOTROPIN is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. 1.2 Adult Patients GENOTROPIN is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria: Adult Onset (AO): Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies...

Mechanism: In vitro, preclinical, and clinical tests have demonstrated that GENOTROPIN lyophilized powder is therapeutically equivalent to human growth hormone of pituitary origin and achieves similar pharmacokinetic profiles in normal adults. In pediatric patients who have growth hormone deficiency (GHD), have Prader-Willi syndrome (PWS), were born small for gestational age (SGA), have Turner syndrome (TS), or have Idiopathic short stature (ISS), treatment with GENOTROPIN stimulates linear growth. In patients with GHD or PWS, treatment with GENOTROPIN also normalizes concentrations of IGF-I...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 12, 2008 Supplement 60 · Efficacy LetterLabelSummary Review
  • Apr 27, 2006 Supplement 49 · Efficacy LabelLetterReview
  • Jul 25, 2001 Supplement 31 · Efficacy · priority review LabelReviewLetter
  • Jun 20, 2000 Supplement 23 · Efficacy · priority review Letter
  • Oct 31, 1997 Supplement 8 · Efficacy Review
  • Aug 24, 1995 Original approval · Type 5 - New Formulation or New Manufacturer
13 products under this application
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.6MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.6MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.2MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN · SOMATROPIN 5.8MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.8MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.5MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.4MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.4MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 1.2MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN · SOMATROPIN 13.8MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 2MG/VIAL · INJECTABLE, INJECTION · Prescription
  • GENOTROPIN PRESERVATIVE FREE · SOMATROPIN 0.8MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dose omission by device18,613
  • device leakage9,818
  • device breakage8,090
  • device mechanical issue7,703
  • device information output issue7,074
  • device issue5,025
  • wrong technique in device usage process4,667
  • device use error3,272
  • poor quality device used3,103
  • device physical property issue2,983
  • device use issue2,625
  • device delivery system issue2,349

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004220
2005196
2006224
2007246
2008187
2009317
2010563
2011493
20121,581
2013489
2014557
2015733
2016921
20171,186
20181,911
20191,657
20201,894
20213,374
20225,194
20238,591
20249,365
20258,370
20265,088

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Genotropin (Somatropin)

2024 spending

$26.8M

Beneficiaries

1,495

11,033 claims

Per beneficiary

$17,930

$625.62 per unit

View as table
YearSpending
2020$18,270,051
2021$22,168,193
2022$23,852,204
2023$27,196,427
2024$26,804,746

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Pfizer · Also marketed as Genotropin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.